-
1دورية أكاديمية
المؤلفون: Neven, P, Fasching, P A, Chia, S, Jerusalem, Guy, De Laurentiis, M, Im, S-A, Petrakova, K, Bianchi, G V, Martín, M, Nusch, A, Sonke, G S, De la Cruz-Merino, L, Beck, J T, Zarate, J P, Wang, Y, Chakravartty, A, Wang, C, Slamon, D J
المصدر: Breast Cancer Research, 25 (1), 103 (2023-08-31)
مصطلحات موضوعية: Advanced breast cancer, CDK4/6 inhibitor, First line, Overall survival, Ribociclib, Fulvestrant, ribociclib, Humans, Female, Proportional Hazards Models, Postmenopause, Breast Neoplasms/drug therapy, Breast Neoplasms, Oncology, Cancer Research, Human health sciences, Sciences de la santé humaine, Oncologie
العلاقة: urn:issn:1465-5411; urn:issn:1465-542X
الوصول الحر: https://orbi.uliege.be/handle/2268/313198Test
-
2دورية أكاديمية
المؤلفون: Slamon, D J, Neven, P, Chia, S, JERUSALEM, Guy, De Laurentiis, M, Im, S, Petrakova, K, Valeria Bianchi, G, Martín, M, Nusch, A, Sonke, G S, De la Cruz-Merino, L, Beck, J T, Ji, Y, Wang, C, Deore, U, Chakravartty, A, Zarate, J P, Taran, T, Fasching, P A
المصدر: Annals of Oncology, 32 (8), 1015-1024 (2021)
مصطلحات موضوعية: CDK4/6 inhibitor, advanced breast cancer, overall survival, ribociclib, Aminopyridines, Purines, Receptors, Estrogen, Receptors, Progesterone, Fulvestrant, ERBB2 protein, human, Receptor, ErbB-2, Adolescent, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Double-Blind Method, Female, Humans, Postmenopause, Breast Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Hematology, Oncology, Human health sciences, Sciences de la santé humaine, Oncologie
العلاقة: https://api.elsevier.com/content/article/PII:S0923753421015532?httpAccept=text/xmlTest; urn:issn:0923-7534; urn:issn:1569-8041
الوصول الحر: https://orbi.uliege.be/handle/2268/292335Test